Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III
Launched by SAMSUNG MEDICAL CENTER · Apr 12, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Samsung Lymphoma Cohort Study III is a research trial aimed at understanding how patients with aggressive forms of lymphoma, including both Hodgkin and non-Hodgkin lymphomas, respond to treatments. This study will involve patients who are 20 years or older and have been diagnosed with these types of lymphoma. Participants will be treated according to standard care practices, and researchers will closely monitor their health, including how well the treatment is working and their overall survival.
To be eligible for this study, patients must have a confirmed diagnosis of Hodgkin or non-Hodgkin lymphoma and need systemic chemotherapy aimed at curing their disease. Unfortunately, individuals with certain other blood cancers, like myeloid malignancies or multiple myeloma, cannot participate. Throughout the study, researchers will collect blood samples to analyze the disease and its response to treatment. This research aims to improve our understanding of lymphoma and help develop better treatment options in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas
- • 2. 20 years
- • 3. Patients requiring systemic chemotherapy with curative intent
- • 4. Written informed consent
- Exclusion Criteria:
- • 1. Myeloid malignancy
- • 2. Multiple myeloma
- • 3. Patients do not require systemic chemotherapy with curative intent
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Seok Jin Kim, MD, PhD
Principal Investigator
Samsung Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials